The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of TGF-β inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).
 
Hyo Song Kim
No Relationships to Disclose
 
Jin-Hee Ahn
No Relationships to Disclose
 
Jeong Eun Kim
No Relationships to Disclose
 
Jung Yong Hong
Research Funding - AstraZeneca
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Sung Hyun Kim
No Relationships to Disclose
 
Jin Lee
Employment - medpacto
Stock and Other Ownership Interests - medpacto
Travel, Accommodations, Expenses - medpacto
 
Sunjin Hwang
Employment - medpacto
Leadership - medpacto
Stock and Other Ownership Interests - Gilead Sciences
 
Min Kyung Jeon
No Relationships to Disclose
 
Seong-Jin Kim
Employment - medpacto; medpacto (I)
Leadership - medpacto; medpacto (I)
Stock and Other Ownership Interests - medpacto; medpacto (I); Theragen Etex; Theragen Etex (I)
Research Funding - medpacto
Patents, Royalties, Other Intellectual Property - Bag2 detection patent DRAK2 inhibitor patent
Travel, Accommodations, Expenses - medpacto; Theragen Etex